T regulatory cells, the evolution of targeted immunotherapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1806, Issue 1, 2010, Pages 7-17

  Nizar, S ^a,b   Meyer, B ^a   Galustian, C ^a   Kumar, D ^b   Dalgleish, A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cancer; FOXP3; Immunotherapy; T regulatory; Tregs

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; BEVACIZUMAB; CD134 ANTIGEN; CELL PROTEIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DAT 1; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR ANIBODY; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR LIGAND PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; IMMUNOTOXIN LMB2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; IPILIMUMAB; PEPTIDE VACCINE; PREDNISOLONE; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; TICILIMUMAB; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CHEMOTAXIS; CLINICAL TRIAL; DENDRITIC CELL; DRUG FATALITY; EFFECTOR CELL; HUMAN; IMMUNOREGULATION; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFER; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE DRUG DOSE; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY LOSS; VISUAL IMPAIRMENT;

ANIMALS; ANTIGENS, CD; DENDRITIC CELLS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 77953807455     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.02.001     Document Type: Review

References (128)

1. Nishizuka Y., Sakakura T. Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 1969, 166:753-755.
2. Kojima A., Tanaka-Kojima Y., Sakakura T., Nishizuka Y. Prevention of postthymectomy autoimmune thyroiditis in mice. Lab. Invest. 1976, 34:601-605.
3. Gershon R.K., Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970, 18:723-737.
4. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155:1151-1164.
5. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 1998, 188:287-296.
6. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 1998, 10:1969-1980.
7. Suri-Payer E., Cantor H. Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4(+)CD25(+) T cells. J. Autoimmun. 2001, 16:115-123.
8. Asseman C., Mauze S., Leach M.W., Coffman R.L., Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 1999, 190:995-1004.
9. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737-742.
10. Roncarolo M.G., Gregori S., Battaglia M., Bacchetta R., Fleischhauer K., Levings M.K. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 2006, 212:28-50.
11. Carrier Y., Yuan J., Kuchroo V.K., Weiner H.L. Th3 cells in peripheral tolerance. I: induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. J. Immunol. 2007, 178:179-185.
12. + cells mediate active suppression. J. Immunol. 1995, 155:910-916.
13. - T cells. Int. Immunol. 1998, 10:775-783.
14. + suppressor T cells. J. Clin. Invest. 2004, 114:1218-1221.
15. Myers L., Croft M., Kwon B.S., Mittler R.S., Vella A.T. Peptide-specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-beta-based suppression. J. Immunol. 2005, 174:7625-7632.
16. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
17. Nizar S., Copier J., Meyer B., Bodman-Smith M., Galustian C., Kumar D., Dalgleish A. T-regulatory cell modulation: the future of cancer immunotherapy?. Br. J. Cancer 2009, 100:1697-1703.
18. + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008, 93:193-200.
19. Powell D.J., Felipe-Silva A., Merino M.J., Ahmadzadeh M., Allen T., Levy C., White D.E., Mavroukakis S., Kreitman R.J., Rosenberg S.A., Pastan I. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J. Immunol. 2007, 179:4919-4928.
20. Iellem A., Mariani M., Lang R., Recalde H., Panina-Bordignon P., Sinigaglia F., D'Ambrosio D. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 2001, 194:847-853.
21. +CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol. 2006, 177:7398-7405.
22. Tan M.C., Goedegebuure P.S., Belt B.A., Flaherty B., Sankpal N., Gillanders W.E., Eberlein T.J., Hsieh C.S., Linehan D.C. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J. Immunol. 2009, 182:1746-1755.
23. Kretschmer K., Apostolou I., Hawiger D., Khazaie K., Nussenzweig M.C., von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 2005, 6:1219-1227.
24. + Tr cells. Blood 2005, 105:1162-1169.
25. Penna G., Giarratana N., Amuchastegui S., Mariani R., Daniel K.C., Adorini L. Manipulating dendritic cells to induce regulatory T cells. Microbes Infect. 2005, 7:1033-1039.
26. + regulatory T cells. Semin. Immunol. 2004, 16:89-98.
27. Godfrey V.L., Wilkinson J.E., Russell L.B. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am. J. Pathol. 1991, 138:1379-1387.
28. Ochs H.D., Ziegler S.F., Torgerson T.R. FOXP3 acts as a rheostat of the immune response. Immunol. Rev. 2005, 203:156-164.
29. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
30. Coffer P.J., Burgering B.M. Forkhead-box transcription factors and their role in the immune system. Nat. Rev. Immunol. 2004, 4:889-899.
31. Hinz S., Pagerols-Raluy L., Oberg H.H., Ammerpohl O., Grussel S., Sipos B., Grutzmann R., Pilarsky C., Ungefroren H., Saeger H.D., Kloppel G., Kabelitz D., Kalthoff H. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res. 2007, 67:8344-8350.
32. Ebert L.M., Tan B.S., Browning J., Svobodova S., Russell S.E., Kirkpatrick N., Gedye C., Moss D., Ng S.P., MacGregor D., Davis I.D., Cebon J., Chen W. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res. 2008, 68:3001-3009.
33. Carson B.D., Lopes J.E., Soper D.M., Ziegler S.F. Insights into transcriptional regulation by FOXP3. Front. Biosci. 2006, 11:1607-1619.
34. + T cells. Eur. J. Immunol. 2007, 37:129-138.
35. Takahashi T., Tagami T., Yamazaki S., Uede T., Shimizu J., Sakaguchi N., Mak T.W., Sakaguchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 2000, 192:303-310.
36. Krummel M.F., Allison J.P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 1996, 183:2533-2540.
37. + regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur. J. Immunol. 2000, 30:1538-1543.
38. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 2002, 3:135-142.
39. Ronchetti S., Zollo O., Bruscoli S., Agostini M., Bianchini R., Nocentini G., Ayroldi E., Riccardi C. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur. J. Immunol. 2004, 34:613-622.
40. + T cells. J. Immunol. 2004, 173:5008-5020.
41. Shevach E.M., Stephens G.L. The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?. Nat. Rev. Immunol. 2006, 6:613-618.
42. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., Solomon M., Selby W., Alexander S.I., Nanan R., Kelleher A., Fazekas de St G.B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 2006, 203:1693-1700.
43. + T reg cells. J. Exp. Med. 2006, 203:1701-1711.
44. Sugamura K., Ishii N., Weinberg A.D. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat. Rev. Immunol. 2004, 4:420-431.
45. + Tregs. Blood 2007, 110:2501-2510.
46. + resting regulatory T cells from activated T cells. J. Immunol. 2006, 176:2808-2816.
47. Thompson R.H., Dong H., Lohse C.M., Leibovich B.C., Blute M.L., Cheville J.C., Kwon E.D. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 2007, 13:1757-1761.
48. Okudaira K., Hokari R., Tsuzuki Y., Okada Y., Komoto S., Watanabe C., Kurihara C., Kawaguchi A., Nagao S., Azuma M., Yagita H., Miura S. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int. J. Oncol. 2009, 35:741-749.
49. Brocker T., Riedinger M., Karjalainen K. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J. Exp. Med. 1997, 185:541-550.
50. + immunoregulatory T cells. J. Exp. Med. 2001, 194:427-438.
51. + regulatory T cells in human thymus. Nature 2005, 436:1181-1185.
52. Chaux P., Favre N., Martin M., Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer 1997, 72:619-624.
53. Chung D.J., Rossi M., Romano E., Ghith J., Yuan J., Munn D.H., Young J.W. Indoleamine 2, 3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009, 114:555-563.
54. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., Carbone D.P., Gabrilovich D.I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166:678-689.
55. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 2004, 4:941-952.
56. LiI Q., Verma M. NF-[kappa]B regulation in the immune system. Nat. Rev. Immunol. 2002, 2:725-734.
57. Larmonier N., Marron M., Zeng Y., Cantrell J., Romanoski A., Sepassi M., Thompson S., Chen X., Andreansky S., Katsanis E. Tumor-derived CD4(+)CD25 (+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol. Immunother. 2006, 56(1):48-59.
58. Smyth M.J., Hayakawa Y., Takeda K., Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2002, 2:850-861.
59. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 2002, 3:999-1005.
60. + T lymphocytes. Inhibition by transforming growth factor-beta. J. Immunol. 1991, 146:3289-3297.
61. + and NK lymphocytes in the direct cell-to-cell interaction. Clin. Immunol. 2004, 112:258-267.
62. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 2005, 202:1075-1085.
63. Gilfillan S., Ho E.L., Cella M., Yokoyama W.M., Colonna M. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat. Immunol. 2002, 3:1150-1155.
64. Simon A.K., Jones E., Richards H., Wright K., Betts G., Godkin A., Screaton G., Gallimore A. Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. Eur. J. Immunol. 2007, 37:758-767.
65. Kripke M.L. Antigenicity of murine skin tumors induced by ultraviolet light. J. Natl. Cancer Inst. 1974, 53:1333-1336.
66. Spellman C.W., Daynes R.A. Ultraviolet light, tumors, and suppressor T cells. Hum. Pathol. 1981, 12:299-301.
67. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
68. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoue F., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
69. +. J. Immunol. 2004, 172:5213-5221.
70. Collison L.W., Pillai M.R., Chaturvedi V., Vignali D.A. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J. Immunol. 2009, 182:6121-6128.
71. + regulatory T cells do not constitutively express IL-35. J. Immunol. 2008, 181:6898-6905.
72. +. J. Immunol. 2007, 178:2883-2892.
73. + T-cell-dependent surveillance. Cancer Res. 1990, 50:3851-3858.
74. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:3539-3543.
75. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., Wu T.C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996, 56:21-26.
76. Khazaie K., von Boehmer H. The impact of CD4(+)CD25(+) Treg on tumor specific CD8(+) T cell cytotoxicity and cancer. Semin. Cancer Biol. 2006, 16:124-136.
77. Chen M.L., Pittet M.J., Gorelik L., Flavell R.A., Weissleder R., von Boehmer H., Khazaie K. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:419-424.
78. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., Toes R.E., Offringa R., Melief C.J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001, 194:823-832.
79. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 2005, 174:2591-2601.
80. + regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One 2006, 1:e129.
81. Galustian C., Labarthe M.C., Bartlett J.B., Dalgleish A.G. Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opin. Biol. Ther. 2004, 4:1963-1970.
82. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007, 56:641-648.
83. Sung C.C., Chang P.Y., Cheng M.F., Sheu L.F., Yao N.S. Successful metronomic low-dose cyclophosphamide therapy in an older patient with advanced mucosa-associated lymphoid tissue lymphoma. Ann. Hematol. 2009, 88(12):386-390.
84. T. Nelius, T. Klatte, W. de Riese, A. Haynes, S. Filleur, Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy, Med. Oncol. (2009) (Electronic publication ahead of print).
85. Jurado J.M., Sanchez A., Pajares B., Perez E., Alonso L., Alba E. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin. Transl. Oncol. 2008, 10:583-586.
86. Lord R., Nair S., Schache A., Spicer J., Somaihah N., Khoo V., Pandha H. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J. Urol. 2007, 177:2136-2140.
87. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4:423-436.
88. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105:2862-2868.
89. + T lymphocytes. Clin. Exp. Immunol. 2007, 150:523-530.
90. + regulatory T cells in a dose-dependent manner. Int. J. Oncol. 2007, 31:1133-1139.
91. M.M. Hipp, N. Hilf, S. Walter, D. Werth, L. Kanz, T. Weinschenk, H. Singh, P. Brossart, Sorafenib but not sunitib affects the induction of immune responses, J. Clin. Oncol. 25 (2007) (ASCO (American Society of Clinical Oncology) Abstract).
92. Passalacqua R., Buti S., Lazzarelli Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC). J. Clin. Oncol. 2008, 26.
93. Lider O., Beraud E., Reshef T., Friedman A., Cohen I.R. Vaccination against experimental autoimmune encephalomyelitis using a subencephalitogenic dose of autoimmune effector T cells. (2) Induction of a protective anti-idiotypic response. J. Autoimmun. 1989, 2:87-99.
94. + regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells. Cell Res. 2007, 17:627-637.
95. Zhang Y., Wang L., Li D., Li N. Taming regulatory T cells by autologous T cell immunization: a potential new strategy for cancer immune therapy. Int. Immunopharmacol. 2009, 9:593-595.
96. + regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2002, 2:1.
97. Kreitman R.J., Batra J.K., Seetharam S., Chaudhary V.K., FitzGerald D.J., Pastan I. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds. Bioconjug. Chem. 1993, 4:112-120.
98. P. Attia, D.J. Powell, Jr., A.V. Maker, R.J. Kreitman, I. Pastan, S.A. Rosenberg, Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J. Immunother. (1997), 29 (2006) 208-214.
99. Kreitman R.J., Wilson W.H., White J.D., Stetler-Stevenson M., Jaffe E.S., Giardina S., Waldmann T.A., Pastan I. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 2000, 18:1622-1636.
100. Waters C.A., Schimke P.A., Snider C.E., Itoh K., Smith K.A., Nichols J.C., Strom T.B., Murphy J.R. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur. J. Immunol. 1990, 20:785-791.
101. Talpur R., Jones D.M., Alencar A.J., Apisarnthanarax N., Herne K.L., Yang Y., Duvic M. CD25 expression is correlated with histological grade and response to Denileukin Diftitox in cutaneous T-cell lymphoma. J. Invest. Dermatol. 2006, 126:575-583.
102. + human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 2007, 120:2723-2733.
103. Attia P., Maker A.V., Haworth L.R., Rogers-Freezer L., Rosenberg S.A. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 2005, 28:582-592.
104. Gerena-Lewis M., Crawford J., Bonomi P., Maddox A.M., Hainsworth J., McCune D.E., Shukla R., Zeigler H., Hurtubise P., Chowdhury T.R., Fletcher B., Dyehouse K., Ghalie R., Jazieh A.R. A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am. J. Clin. Oncol. 2009, 32:269-273.
105. Morse M.A., Hobeika A.C., Osada T., Serra D., Niedzwiecki D., Lyerly H.K., Clay T.M. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008, 112:610-618.
106. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., Zhang A., Dahm P., Chao N., Gilboa E., Vieweg J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005, 115:3623-3633.
107. Kuzel T.M., Li S., Eklund J., Foss F., Gascoyne R., Abramson N., Schwerkoske J.F., Weller E., Horning S.J. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497. Leuk. Lymphoma 2007, 48:2397-2402.
108. Dang N.H., Fayad L., McLaughlin P., Romaguara J.E., Hagemeister F., Goy A., Neelapu S., Samaniego F., Walker P.L., Wang M., Rodriguez M.A., Tong A.T., Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br. J. Haematol. 2007, 138:502-505.
109. Dang N.H., Pro B., Hagemeister F.B., Samaniego F., Jones D., Samuels B.I., Rodriguez M.A., Goy A., Romaguera J.E., McLaughlin P., Tong A.T., Turturro F., Walker P.L., Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br. J. Haematol. 2007, 136:439-447.
110. Frankel A.E., Surendranathan A., Black J.H., White A., Ganjoo K., Cripe L.D. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer 2006, 106:2158-2164.
111. Liu B., Podack E.R., Allison J.P., Malek T.R. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J. Immunol. 1996, 156:1117-1125.
112. Gregor P.D., Wolchok J.D., Ferrone C.R., Buchinshky H., Guevara-Patino J.A., Perales M.A., Mortazavi F., Bacich D., Heston W., Latouche J.B., Sadelain M., Allison J.P., Scher H.I., Houghton A.N. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 2004, 22:1700-1708.
113. Davila E., Kennedy R., Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003, 63:3281-3288.
114. Kwon E.D., Hurwitz A.A., Foster B.A., Madias C., Feldhaus A.L., Greenberg N.M., Burg M.B., Allison J.P. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:8099-8103.
115. + T cell- and IL-2-dependent mechanism. Immunity 1999, 11:483-493.
116. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
117. Keler T., Halk E., Vitale L., O'Neill T., Blanset D., Lee S., Srinivasan M., Graziano R.F., Davis T., Lonberg N., Korman A. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J. Immunol. 2003, 171:6251-6259.
118. Menard C., Ghiringhelli F., Roux S., Chaput N., Mateus C., Grohmann U., Caillat-Zucman S., Zitvogel L., Robert C. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?. Clin. Cancer Res. 2008, 14:5242-5249.
119. Quezada S.A., Peggs K.S., Curran M.A., Allison J.P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 2006, 116:1935-1945.
120. Ribas A., Hauschild A., Kefford C., Punt C., Haanen M. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J. Clin. Oncol. 2008, 26.
121. Fong L., Kwek S.S., O'Brien S., Kavanagh B., McNeel D.G., Weinberg V., Lin A.M., Rosenberg J., Ryan C.J., Rini B.I., Small E.J. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009, 69:609-615.
122. Wolchok J.D., Neyns B., Linette G., Negrier S., Lutzky J., Thomas L., Waterfield W., Schadendorf D., Smylie M., Guthrie T., Grob J.J., Chesney J., Chin K., Chen K., Hoos A., O'Day S.J., Lebbe C. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2009, 11(2):155-164.
123. E.M. Hersh, S.J. O'Day, J. Powderly, K.D. Khan, A.C. Pavlick, L.D. Cranmer, W.E. Samlowski, G.M. Nichol, M.J. Yellin, J.S. Weber, A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma, Invest. New Drugs (2010) (Electronic publication ahead of print).
124. Saenger Y.M., Wolchok J.D. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun. 2008, 8:1.
125. Piconese S., Valzasina B., Colombo M.P. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 2008, 205:825-839.
126. + regulatory T cell-mediated suppression of antitumor immunity. Int. J. Cancer 2009, 125:630-638.
127. Turk M.J., Guevara-Patino J.A., Rizzuto G.A., Engelhorn M.E., Sakaguchi S., Houghton A.N. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 2004, 200:771-782.
128. Ramirez-Montagut T., Chow A., Hirschhorn-Cymerman D., Terwey T.H., Kochman A.A., Lu S., Miles R.C., Sakaguchi S., Houghton A.N., van den Brink M.R. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J. Immunol. 2006, 176:6434-6442.